Myriad Genetics (MYGN) Total Current Liabilities (2010 - 2026)

Myriad Genetics (MYGN) has reported Total Current Liabilities for 17 consecutive years, with $130.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 13.83% year-over-year to $130.2 million; the TTM figure through Mar 2026 stood at $130.2 million (down 13.83% YoY), while the FY2025 annual figure was $133.8 million, down 18.46% from the prior year.
• Total Current Liabilities declined to $130.2 million in Q1 2026 per MYGN's latest filing, from $133.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $221.1 million in Q2 2023 and bottomed at $119.7 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $156.4 million across 5 years, with a median of $148.9 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities slumped 55.83% — and 2023, when it surged 84.71%.
• Myriad Genetics' Total Current Liabilities stood at $137.2 million in 2022, then advanced by 13.63% to $155.9 million in 2023, then gained by 5.26% to $164.1 million in 2024, then declined by 18.46% to $133.8 million in 2025, then slipped by 2.69% to $130.2 million in 2026.
• Business Quant data shows MYGN's Total Current Liabilities at $130.2 million in Q1 2026, $133.8 million in Q4 2025, and $148.0 million in Q3 2025.